Purchase Order 75N91020P00531

<p>The National Cancer Institute awarded a purchase order to Covaris, LLC for $12,750.00 on November 9, 2018, with ultimate completion on November 9, 2019. Work is performed in Woburn, Massachusetts. The order is firm fixed price with no set-aside designation. Covaris is a small business concern specializing in genomic research equipment and sample preparation technologies utilizing proprietary Adaptive Focused Acoustics technology.</p>

<p>The National Cancer Institute awarded a purchase order to Covaris, LLC for $4,950.00 on February 1, 2018, with a final completion date of March 27, 2019. Place of performance is Bethesda, Maryland. The order is firm fixed price with no set-aside designation. Covaris is a small business concern based in Woburn, Massachusetts, specializing in genomic research equipment and sample preparation technologies.</p>

The National Cancer Institute awarded a purchase order to Covaris, LLC valued at $9,750.00 on March 16, 2018, for genomic research equipment and technologies. No set-aside applied. Place of performance is Bethesda, Maryland. The order carries a firm fixed price structure and an ultimate completion date of April 20, 2019. Covaris manufactures advanced genomic research instruments utilizing proprietary Adaptive Focused Acoustics technology, serving federal research agencies with specialized...

<p>The National Cancer Institute awarded a purchase order to Covaris, LLC for a Covaris ME220 Focused Ultrasonicator for Chromatin and DNA Shearing valued at $55,513.00 on August 7, 2019. The order carries a Total Small Business set-aside designation. Performance occurs at Woburn, Massachusetts. The underlying solicitation was posted July 5, 2019, with a due date of July 12, 2019. Ultimate completion is scheduled for October 2, 2019. The contract is firm fixed price.</p>

<p>The National Institutes of Health awarded a purchase order to Covaris, LLC for $35,372.00 on July 15, 2019 for supply and installation of a Covaris S220 focused ultrasonicator. Place of performance is Woburn, Massachusetts. The order carries firm fixed pricing with an ultimate completion date of September 10, 2019.</p>

The National Human Genome Research Institute awarded a purchase order to Covaris, LLC for a one-year service plan covering LE220-PLUS equipment (serial number 3388 and WCS 5177) with a ceiling value of $17,255.00, awarded May 7, 2020, with performance through July 1, 2021. Place of performance is Woburn, Massachusetts. The order is firm-fixed-price with no set-aside designation. Covaris is a small business concern specializing in genomic research instrumentation and associated maintenance and...

<p>The National Cancer Institute awarded a purchase order to Covaris, LLC for one E220 focused-ultrasonicator instrument valued at $132,195.00 on August 22, 2017. This is a Total Small Business set-aside, firm fixed-price acquisition. The ultrasonicator is procured for sample preparation and analysis at the National Cancer Institute facility in Rockville, Maryland. The order carries an ultimate completion date of October 17, 2017.</p>

<p>The NIH Clinical Center awarded a purchase order to Covaris, LLC for $24,015.00 on August 15, 2018, for firm-fixed-price delivery of genomic research equipment and accessories. Work is performed at the awardee's facility in Woburn, Massachusetts. The order carried no set-aside designation and was completed by August 15, 2018.</p>

<p>The National Cancer Institute awarded a purchase order to Covaris, LLC for maintenance of a Covaris E220 instrument located in Dr. Pedro Batista's lab at Bethesda, Maryland, with a ceiling value of $13,133.00 and an award date of November 7, 2019. The order is firm fixed price with an ultimate completion date of November 9, 2020. No set-aside was applied.</p>

<p>The National Cancer Institute awarded a purchase order to Covaris, LLC for maintenance of a Covaris E220 ultrasonicator (serial number 003927) valued at $10,045.00, with an award date of April 21, 2020. The one-year maintenance contract runs from April 21, 2020 through April 20, 2021. Place of performance is Bethesda, Maryland. The contract carries firm fixed-price pricing and no set-aside designation.</p>